Tuberculosis in Patients with Primary Myelofibrosis During Ruxolitinib Therapy: Case Series and Literature Review

References

• Tefferi A. Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management. Am J Hematol. 2018;93(12):1551–1560. doi:10.1002/ajh.2523030039550
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Mesa RA, Gotlib J, et al. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, Phase 3 COMFORT-I trial. J Hematol Oncol. 2017;10(1):55. doi:10.1186/s13045-017-0417-z28228106
   PubMed Web of Science ®Google Scholar
• Harrison CN, Vannucchi AM, Kiladjian JJ, et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016;30(8):1701–1707. doi:10.1038/leu.2016.14827211272
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372(5):426–435.25629741
   PubMed Web of Science ®Google Scholar
• Romano M, Sollazzo D, Trabanelli S, et al. Mutations in JAK2 and calreticulin genes are associated with specific alterations of the immune system in myelofibrosis. Oncoimmunology. 2017;6(10):e1345402. doi:10.1080/2162402X.2017.134540229123956
   PubMed Web of Science ®Google Scholar
• Wang JC, Sindhu H, Chen C, et al. Immune derangements in patients with myelofibrosis: the role of Treg, Th17, and sIL2Ralpha. PLoS One. 2015;10(3):e0116723.25793623
   PubMed Web of Science ®Google Scholar
• Rudolph J, Heine A, Quast T, et al. The JAK inhibitor ruxolitinib impairs dendritic cell migration via off-target inhibition of ROCK. Leukemia. 2016;30(10):2119–2123. doi:10.1038/leu.2016.15527220666
   PubMed Web of Science ®Google Scholar
• Heine A, Held SA, Daecke SN, et al. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood. 2013;122(7):1192–1202.23770777
   PubMed Web of Science ®Google Scholar
• Schonberg K, Rudolph J, Vonnahme M, et al. JAK inhibition impairs NK cell function in myeloproliferative neoplasms. Cancer Res. 2015;75(11):2187–2199. doi:10.1158/0008-5472.CAN-14-319825832652
   PubMed Web of Science ®Google Scholar
• Parampalli Yajnanarayana S, Stübig T, Cornez I, et al. JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms. Br J Haematol. 2015;169(6):824–833. doi:10.1111/bjh.1337325824483
   PubMed Web of Science ®Google Scholar
• Keohane C, Kordasti S, Seidl T, et al. JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells. Br J Haematol. 2015;171(1):60–73. doi:10.1111/bjh.1351926075866
   PubMed Web of Science ®Google Scholar
• Polverelli N, Breccia M, Benevolo G, et al. Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients. Am J Hematol. 2017;92(1):37–41. doi:10.1002/ajh.2457227701770
   PubMed Web of Science ®Google Scholar
• Baddley JW, Cantini F, Goletti D, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-alpha agents). Clin Microbiol Infect. 2018;24(Suppl 2):S10–S20. doi:10.1016/j.cmi.2017.12.02529459143
   PubMed Web of Science ®Google Scholar
• Mikulska M, Lanini S, Gudiol C, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52). Clin Microbiol Infect. 2018;24(Suppl 2):S71–S82. doi:10.1016/j.cmi.2018.02.00329447988
   PubMed Web of Science ®Google Scholar
• Tremblay D, King A, Li L, et al. Risk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: a dual-center, propensity score-matched analysis. Leuk Lymphoma. 2019;61(3):660–667.31711337
   PubMed Web of Science ®Google Scholar
• Komatsu N, Kirito K, Shimoda K, et al. Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis. Int J Hematol. 2017;105(3):309–317. doi:10.1007/s12185-016-2130-z27832516
   PubMed Web of Science ®Google Scholar
• Lussana F, Cattaneo M, Rambaldi A, Squizzato A. Ruxolitinib-associated infections: a systematic review and meta-analysis. Am J Hematol. 2018;93(3):339–347. doi:10.1002/ajh.2497629150886
   PubMed Web of Science ®Google Scholar
• Hultcrantz M, Wilkes SR, Kristinsson SY, et al. Risk and cause of death in patients diagnosed with myeloproliferative neoplasms in Sweden between 1973 and 2005: a population-based study. J Clin Oncol. 2015;33(20):2288–2295. doi:10.1200/JCO.2014.57.665226033810
   PubMed Web of Science ®Google Scholar
• Polverelli N, Palumbo GA, Binotto G, et al. Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: a multicenter study on 446 patients. Hematol Oncol. 2018;36(3):561–569. doi:10.1002/hon.2509
   Web of Science ®Google Scholar
• Colomba C, Rubino R, Siracusa L, et al. Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report. BMC Res Notes. 2012;5:552. doi:10.1186/1756-0500-5-55223039051
   PubMedGoogle Scholar
• Kim Y-K, Lee SR, Park Y, et al. Efficacy of ruxolitinib in Korean myelofibrosis patients and cases complicated TB lymphadenitis during the treatment. Blood. 2013;122(21):1596. doi:10.1182/blood.V122.21.1596.1596
   Web of Science ®Google Scholar
• Hopman RK, Lawrence SJ, Oh ST. Disseminated tuberculosis associated with ruxolitinib. Leukemia. 2014;28(8):1750–1751. doi:10.1038/leu.2014.10424625550
   PubMed Web of Science ®Google Scholar
• Chen YH, Lee CH, Pei SN. Pulmonary tuberculosis reactivation following ruxolitinib treatment in a patient with primary myelofibrosis. Leuk Lymphoma. 2015;56(5):1528–1529.25213182
   PubMed Web of Science ®Google Scholar
• Keizer S, Gerritsen R, Jauw Y, Janssen J, Koopman B, Bresser P. Fatal tuberculosis during treatment with ruxolitinib. Ned Tijdschr Geneeskd. 2015;159:A8650–A8650.25990328
   PubMedGoogle Scholar
• Palandri F, Polverelli N, Catani L, Vianelli N. Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge. Ann Hematol. 2015;94(3):519–520. doi:10.1007/s00277-014-2183-025172457
   PubMed Web of Science ®Google Scholar
• Shamil E, Cunningham D, Wong BLK, Jani P. Ruxolitinib associated tuberculosis presenting as a neck lump. Case Rep Infect Dis. 2015;2015:1–3. doi:10.1155/2015/284168
   Google Scholar
• Abidi MZ, Haque J, Varma P, et al. Reactivation of pulmonary tuberculosis following treatment of myelofibrosis with ruxolitinib. Case Rep Hematol. 2016;2016:2389038.27843657
   PubMedGoogle Scholar
• Branco B, Metsu D, Dutertre M, et al. Use of rifampin for treatment of disseminated tuberculosis in a patient with primary myelofibrosis on ruxolitinib. Ann Hematol. 2016;95(7):1207–1209. doi:10.1007/s00277-016-2684-027113251
   PubMed Web of Science ®Google Scholar
• Malkan UY, Haznedaroglu IC. A myelofibrosis case that develops mycobacterial infection after ruxolitinib treatment. Int J Clin Exp Med. 2017;10(4):7304–7307.
   Web of Science ®Google Scholar
• Neethu C, James J, Prabhu R. Reactivation of a common infection following treatment with a novel agent for an uncommon disease-ruxolitinib associated tuberculosis: two cases. J Pharm Sci Res. 2017;9(12):2437–2439.
   Google Scholar
• Patil V, Wasekar N, Jijina F, Mohite A. Ruxolitinib-associated tuberculosis - a rare complication of a novel drug! Int J Med Sci Public Health. 2017;6(3):1. doi:10.5455/ijmsph.2017.0846912092016
   Google Scholar
• Pepeler MS, Ozkurt ZN, Guzel OT, Akyurek N. Tuberculosis reactivation related with ruxolitinib in a patient with primary myelofibrosis. J Infect Dev Ctries. 2018;12(10):926–928. doi:10.3855/jidc.999332004164
   PubMed Web of Science ®Google Scholar
• Tsukamoto Y, Kiyasu J, Tsuda M, et al. Fatal disseminated tuberculosis during treatment with ruxolitinib plus prednisolone in a patient with primary myelofibrosis: a case report and review of the literature. Intern Med. 2018;57(9):1297–1300. doi:10.2169/internalmedicine.9165-1729279479
   PubMed Web of Science ®Google Scholar
• Lescuyer S, Ledoux MP, Gravier S, et al. Tuberculosis and atypical mycobacterial infections in ruxolitinib-treated patients with primary or secondary myelofibrosis or polycythemia vera. Int J Infect Dis. 2019;80:134–136. doi:10.1016/j.ijid.2019.01.00230639623
   PubMed Web of Science ®Google Scholar
• Khalid F, Damlaj M, AlZahrani M, Abuelgasim KA, Gmati GE. Reactivation of tuberculosis following ruxolitinib therapy for primary myelofibrosis: case series and literature review. Hematol Oncol Stem Cell Ther. 2020. doi:10.1016/j.hemonc.2020.02.003
   Google Scholar
• Sakiyama E, Chinen Y, Tsukamoto T, et al. Tuberculosis peritonitis during treatment of polycythemia vera with ruxolitinib. Infect Drug Resist. 2020;13:1017–1021. doi:10.2147/IDR.S24903032308443
   PubMed Web of Science ®Google Scholar
• Russell DG, Cardona PJ, Kim MJ, Allain S, Altare F. Foamy macrophages and the progression of the human tuberculosis granuloma. Nat Immunol. 2009;10(9):943–948. doi:10.1038/ni.178119692995
   PubMed Web of Science ®Google Scholar
• Heine A, Brossart P, Wolf D. Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? Blood. 2013;122(23):3843–3844. doi:10.1182/blood-2013-10-53110324288410
   PubMed Web of Science ®Google Scholar
• Favalli EG, Desiati F, Atzeni F, et al. Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients. Autoimmun Rev. 2009;8(3):266–273. doi:10.1016/j.autrev.2008.11.00219022409
   PubMed Web of Science ®Google Scholar
• Warzocha K, Homenda W, Pluta A, et al. Ruksolitynib w terapii chorych na mielofibrozę — pytania i odpowiedzi. Hematologia. 2019;9(4):269–284. doi:10.5603/Hem.2018.0035
   Google Scholar